GCPII imaging and cancer.
Glutamate carboxypeptidase II (GCPII) in the central nervous system is referred to as the prostate-specific membrane antigen (PSMA) in the periphery. PSMA serves as a target for imaging and treatment of prostate cancer and because of its expression in solid tumor neovasculature has the potential to be used in this regard for other malignancies as well. An overview of GCPII/PSMA in cancer, as well as a discussion of imaging and therapy of prostate cancer using a wide variety of PSMA-targeting agents is provided.
Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical School, Baltimore, MD 21231, USA.
C A
CA
Foss
R C
RC
Mease
S Y
SY
Cho
H J
HJ
Kim
M G
MG
Pomper
D000818:Animals; D000954:Antigens, Surface / Q000235:genetics / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D043425:Glutamate Carboxypeptidase II / Q000235:genetics / Q000378:metabolism; D018698:Glutamic Acid / Q000378:metabolism; D006801:Humans; D008297:Male; D057054:Molecular Imaging / Q000379:methods*; D009369:Neoplasms / Q000175:diagnosis* / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D011467:Prostate / Q000201:enzymology / Q000378:metabolism / Q000473:pathology; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000201:enzymology / Q000235:genetics / Q000473:pathology
D000954:Antigens, Surface; D018698:Glutamic Acid; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II